Information for Healthcare Providers *revised January 8, 2021

Product Name	Pfizer-BioNech COVID-19 Vaccine	Moderna COVID-19 Vaccine	
Product Monogrpah	https://covid-vaccine.canada.ca/info/pdf/pfizer- biontech-covid-19-vaccine-pm1-en.pdf		
Date the vaccine was authorized in Canada	December 9, 2020	December 23, 2020	
Ages that are eligible for the vaccine	16 years and older	18 years and older	
Effectiveness	95.0% (7 days after dose 2 in individuals without evidence of prior SARS-CoV-2 infection)		
Dose for the vaccine	0.3 mL (30mcg of mRNA)	0.5 mL (100 mcg of mRNA)	
Type of vaccine	mRNA	mRNA	
Diluent*	Yes 1.8 mL 0.9% sodium chloride provided by the National Operation Centre (NOC) / manufacture (NOTE: do not use other diluents)		
Does per vial	5 doses	10 doses	
Multiple doses	Yes (2 doses)**	Yes (2 doses)**	
Interval of doses	21 days apart (minimum interval 19 days; alternate schedule 28 days apart)	28 days apart (minimum interval 21 days; alternative interval - none)	
Delay in dose 2 of vaccine series	Second dose should be provided as soon as possible, does not require restarting the series	Second does should be provided as soon as possible, does not require restarting the series	
Route of administration	Intramuscular injection into the deltoid muscle	Intramuscular injection into the deltoid muscle	
Storage*	 Store at: -80 °C to -60 °C Protected from light, in the original package Thawed unpunctured vials (prior to dilution) Store at: +2 °C to +8 °C - for up to 120 hours (5 days) Store at: room temperature (up to +25 °C) for no more than 2 hours Minimize exposure to light (room light, direct sunlight and ultraviolet light) NOTE: do not refreeze thawed vials 	 Store at: - 25 °C to - 15 °C Do not store with dry ice Do not store below - 40 °C Thawed unpunctured vials Store at: + 2 °C to + 8 °C for up to 30 days Store at: + 8 °C to + 25 °C for up to 12 hours NOTE: do not refreeze thawed vials 	

	 Thawed punctured vials (after dilution) Store at: + 2 °C to + 25 °C Vaccine must be used within 6 hours from the time of dilution (otherwise the vial has to be discarded) 	 Thawed punctured vials Store at: + 2 °C to below + 25 °C Vaccine must be used within 6 hours from the time of first puncture (otherwise the vial has to be discarded) 	
Vaccine efficacy (safety)	This has been determined for those 16 years and older.	This has been determined for those 18 years and older.	
	Pediatrics: • Safety and efficacy has not yet been established for children under the age of 16 years.	Pediatrics: • Safety and efficacy has not yet been established for children.	
	 Pregnant/Breast-feeding women: Safety and efficacy has not yet been established for pregnant/breast-feeding women It is unknown at this point if the Pfizer-BioNTech COVID-19 Vaccine is excreted in human milk. Therefore, any risks to newborns/infants cannot be excluded. 	Pregnant/Breast-feeding women: ■ Safety and efficacy has not yet been established for pregnant/breast-feeding women □ Women who are vaccinated with the Moderna COVID-19 Vaccine during pregnancy are encouraged to enroll in the registry by calling 1-866-663-3762) ■ It is unknown at this point if the Moderna COVID-19 Vaccine is excreted in human milk. Therefore, any risks to newborns/infants cannot be excluded.	
	 Geriatrics: People 65 years of age and older have been included in the clinical studies and their data contributes to the overall efficacy for the Pfizer-BioNTech COVID-19 Vaccine. 	 Geriatrics: People 65 years of age and older have been included in the clinical studies and their data contributes to the overall efficacy for the Moderna COVID-19 Vaccine. 	
	Person with an autoimmune condition or immunosuppressed person COVID-19 vaccines should not be routinely offered until more evidence is made available.	Person with an autoimmune condition or immunosuppressed person COVID-19 vaccines should not be routinely offered until more evidence is made available.	
Eligibility Criteria	Those 16 years of age or older and depending on the phase of the vaccine rollout. ***	Those 18 years of age or older and depending on the phase of rollout. ***	
Side effects of the vaccine	Very common (may affect > 1 in 10 people) Pain at injection site Tiredness Headache Muscle pain	Common or very common side effects (these are generally mild and do not last long) Pain at the injection site Tiredness	

	 Chills Joint pain Fever Uncommon (may affect up to 1 in 100 people) Enlarged lymph nodes *Note: if there are any side effects that are not listed here, they should be report to a healthcare professional. 	 Headache Muscle ache and stiffness Chills Fever Swelling or redness at the injection site Nausea and/or vomiting Enlarged lymph nodes *Note: if there are any side effects that are not listed here, they should be report to a healthcare professional.	
Drug interaction	 No drug interaction studies have been performed to date. The Pfizer-BioNTech COVID-19 Vaccine is NOT to be mixed with other vaccines/products in the same syringe. 	 No drug interaction studies have been performed to date. The Moderna COVID-19 Vaccine is NOT to be mixed with other vaccines/products in the same syringe. 	
Interaction with other vaccines	COVID-19 vaccines should not be given simultaneously with other live or inactivated vaccines at this time	COVID-19 vaccines should not be given simultaneously with other live or inactivated vaccines at this time	
Ingredients	Medicinal ingredient: mRNA Non-medicinal ingredients: • ALC-0315 = ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) • ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide • 1,2-Distearoyl-sn-glycero-3-phosphocholine • cholesterol • dibasic sodium phosphate dehydrate • monobasic potassium phosphate • potassium chloride • sodium chloride • sucrose • water for injection	Medicinal ingredients: mRNA-1273 SARS-CoV-2 Non-medicinal ingredients: • 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) • acetic acid • cholesterol • PEG2000 DMG (1,2-dimyristoyl-racglycerol,methoxy-polyethyleneglycol) • lipid SM-102 • sodium acetate • sucrose • tromethamine • tromethamine hydrochloride • water for injection	
Food/Drug allergy	Individuals should not receive the Pfizer-BioNTech COVID-19 vaccine if they have a history of a severe allergic reaction to a component (substance) of the vaccine. • Known potential allergen is Polyethylene glycol	Individuals should not receive the Moderna COVID-19 Vaccine if they have a history of a severe allergic reaction to a component (substance) of the vaccine. • Known potential allergen is Polyethylene glycol	
Longevity/lasting protection	Unknown at this time	Unknown at this time	
Ordering of the vaccine	TBD	TBD	

- *It is recommended that the vials are clearly labeled with the times for storage/use purposes
- **The NACI recommends the vaccine series is completed with the same COVID-19 vaccine product.
- *** Ontario has developed a plan for vaccine rollout. The plan is as follows:

Ontario	ONTARIO'S COVID-19 VACCINATION PROGRAM*				
S	VACCINE QUANTITY	POPULATION TO BE VACCINATED	DISTRIBUTION SITES		
PHASES	Initial doses vaccinated as planned over 2500 people, with additional shipments arriving over the coming weeks 95000 doses of Pfizer-BioNTech and almost 53000 doses of Moderna vaccines have been delivered An estimated total of over 2M doses is expected in this phase	Residents, essential caregivers, and staff of congregate care settings for seniors Health care workers Adults in Indigenous populations Adult recipients of chronic home health care	Initially, two pilot sites, followed by selected hospital sites in Grey-Lockdown and Red-Control zones, expanding to approximately 21 hospitals across the province ITC homes and Retirement Homes as soon as feasible		
<u></u>	Increasing stock of vaccines available	Continued for health care workers, long term care homes, retirement homes, home care patients with chronic conditions, and additional First Nations communities and Indigenous populations When additional doses are available, populations to be vaccinated TBD**	Expanded vaccination sites		
	Vaccines available for every Ontarian who wants to be immunized	All eligible Ontarians**	Widely available across Ontario		

^{*}Data available as of January 5, 2020

References:

- Canadian National Advisory Committee on Immunization Recommendations Use of COVID-19 Vaccines
- COVID-19 Vaccines for Ontario
- Product Monograph Pfizer-BioNTech COVID-19 Vaccine
- Product Monograph Moderna COVID-19 Vaccine
- Recommendations of the National Advisory Committee on Immunization (NACI) on the use of the Pfizer-BioNTechCOVID-19 vaccine



^{**}Further prioritization may occur within his group based on available vaccine upply, grounded in an ethical and data-driven framework,